Multi-parametric MRI and texture analysis to visualize spatial histologic heterogeneity and tumor extent in glioblastoma

PLoS ONE

Volumn 10, Issue 11, 2015, Pages

  Hu, Leland S ^a,f   Ning, Shuluo ^d   Eschbacher, Jennifer M ^f   Gaw, Nathan ^d   Dueck, Amylou C ^a   Smith, Kris A ^f   Nakaji, Peter ^f   Plasencia, Jonathan ^e   Ranjbar, Sara ^a   Price, Stephen J ^g   Tran, Nhan ^c   Loftus, Joseph ^a   Jenkins, Robert ^a   O'Neill, Brian P ^a   Elmquist, William ^b   Baxter, Leslie C ^f   Gao, Fei ^d   Frakes, David ^e   Karis, John P ^f   Zwart, Christine ^a   Swanson, Kristin R ^a   Sarkaria, Jann ^a   Wu, Teresa ^a,d   Mitchell, J Ross ^a   Li, Jing ^a,d   more..

^a MAYO CLINIC   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

^c TRANSLATIONAL GENOMICS RESEARCH INSTITUTE   (United States)

^d ARIZONA STATE UNIVERSITY   (United States)

^e Arizona State University   (United States)

^f BARROW NEUROLOGICAL INSTITUTE   (United States)

^g UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CLINICAL ARTICLE; CONTRAST ENHANCEMENT; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DIFFUSION TENSOR IMAGING; GLIOBLASTOMA; HUMAN; HUMAN TISSUE; IMAGE ANALYSIS; IMAGE GUIDED BIOPSY; MULTIPARAMETRIC MAGNETIC RESONANCE IMAGING; PREDICTIVE VALUE; PREOPERATIVE PERIOD; SENSITIVITY AND SPECIFICITY; TEXTURE ANALYSIS; VALIDATION PROCESS; ALGORITHM; COMPUTER ASSISTED DIAGNOSIS; DIAGNOSTIC IMAGING; MACHINE LEARNING; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOLOGY; PROCEDURES; RADIOGRAPHY;

CONTRAST MEDIUM;

ALGORITHMS; CONTRAST MEDIA; DIFFUSION TENSOR IMAGING; GLIOBLASTOMA; HUMANS; IMAGE INTERPRETATION, COMPUTER-ASSISTED; IMAGE-GUIDED BIOPSY; MACHINE LEARNING; MAGNETIC RESONANCE IMAGING; RADIOGRAPHY;

EID: 84957567984     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0141506     Document Type: Article

References (30)

1. Bonavia R, Inda MM, Cavenee WK, Furnari FB. Heterogeneity maintenance in glioblastoma: a social network. Cancer Res. 2011 Jun 15; 71(12):4055-60. doi: 10.1158/0008-5472.CAN-11-0153 PMID: 21628493
2. Marusyk A, Almendro V, Polyak K. Intra-tumour heterogeneity: a looking glass for cancer? Nat Rev Cancer. 2012 Apr 19; 12(5):323-34. doi: 10.1038/nrc3261 PMID: 22513401
3. Agarwal S, Sane R, Oberoi R, Ohlfest JR, Elmquist WF. Delivery of molecularly targeted therapy to malignant glioma, a disease of the whole brain. Expert Rev Mol Med. 2011 May 13; 13:e17. Review. doi: 10.1017/S1462399411001888 PMID: 21676290
4. Cancer Genome Atlas Research Network. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature. 2008 Oct 23; 455(7216):1061-8. doi: 10.1038/nature07385 PMID: 18772890
5. Price SJ, Jena R, Burnet NG, Hutchinson PJ, Dean AF, Peña A, et al. Improved delineation of glioma margins and regions of infiltration with the use of diffusion tensor imaging: an image-guided biopsy study. AJNR Am J Neuroradiol. 2006 Oct; 27(9):1969-74. PMID: 17032877
6. Sottoriva A, Spiteri I, Piccirillo SG, Touloumis A, Collins VP, Marioni JC, et al. Intratumor heterogeneity in human glioblastoma reflects cancer evolutionary dynamics. Proc Natl Acad Sci U S A. 2013 Mar 5; 110(10):4009-14. doi: 10.1073/pnas.1219747110 PMID: 23412337
7. Barajas RF Jr, Phillips JJ, Parvataneni R, Molinaro A, Essock-Burns E, Bourne G, et al. Regional variation in histopathologic features of tumor specimens from treatment-naive glioblastoma correlates with anatomic and physiologic MR Imaging. Neuro Oncol. 2012 Jul; 14(7):942-54. doi: 10.1093/neuonc/nos128 PMID: 22711606
8. Ellingson BM, Malkin MG, Rand SD, Connelly JM, Quinsey C, LaViolette PS, et al. Validation of functional diffusion maps (fDMs) as a biomarker for human glioma cellularity. J Magn Reson Imaging. 2010 Mar; 31(3):538-48. doi: 10.1002/jmri.22068 PMID: 20187195
9. Stadlbauer A, Ganslandt O, Buslei R, Hammen T, Gruber S, Moser E, et al. Gliomas: histopathologic evaluation of changes in directionality and magnitude of water diffusion at diffusion-tensor MR imaging. Radiology. 2006 Sep; 240(3):803-10. PMID: 16926329
10. LaViolette PS, Mickevicius NJ, Cochran EJ, Rand SD, Connelly J, Bovi JA, et al. Precise ex vivo histological validation of heightened cellularity and diffusion-restricted necrosis in regions of dark apparent diffusion coefficient in 7 cases of high-grade glioma. Neuro Oncol. 2014 Dec; 16(12):1599-606. doi: 10.1093/neuonc/nou142 PMID: 25059209
11. Haralick RM, Shanmugam K, and Dinstein I. Textural features for image classification. Systems, Man and Cybernetics, IEEE Transactions on 6 (1973): 610-621.
12. Ojala T, Pietikainen M, Maenpaa T. Multiresolution gray-scale and rotation invariant texture classification with local binary patterns. Pattern Analysis and Machine Intelligence, IEEE Transactions on 24.7 (2002): 971-987.
13. Brown R, Zlatescu M, Sijben A, Roldan G, Easaw J, Forsyth P, et al. The use of magnetic resonance imaging to noninvasively detect genetic signatures in oligodendroglioma. Clin Cancer Res. 2008 Apr 15; 14(8):2357-62. doi: 10.1158/1078-0432.CCR-07-1964 PMID: 18413825
14. Drabycz S, Roldán G, de Robles P, Adler D, McIntyre JB, Magliocco AM, et al. An analysis of image texture, tumor location, and MGMT promoter methylation in glioblastoma using magnetic resonance imaging. Neuroimage. 2010 Jan 15; 49(2):1398-405. doi: 10.1016/j.neuroimage.2009.09.049 PMID: 19796694
15. Weber MA, Henze M, Tüttenberg J, Stieltjes B, Meissner M, Zimmer F, et al. Biopsy targeting gliomas: do functional imaging techniques identify similar target areas? Invest Radiol. 2010 Dec; 45(12):755-68. doi: 10.1097/RLI.0b013e3181ec9db0 PMID: 20829706
16. Hu LS, Eschbacher JM, Dueck AC, Heiserman JE, Liu S, Karis JP, et al. Correlations between perfusion MR imaging cerebral blood volume, microvessel quantification, and clinical outcome using stereotactic analysis in recurrent high-grade glioma. AJNR Am J Neuroradiol. 2012 Jan; 33(1):69-76. doi: 10.3174/ajnr.A2743 PMID: 22095961
17. Hu LS, Eschbacher JM, Heiserman JE, Dueck AC, Shaphiro WR, Liu S, et al. Reevaluating the imaging definition of tumor progression: perfusion MRI quantifies recurrent glioblastoma tumor fraction, pseudoprogression, and radiation necrosis to predict survival. Neuro Oncol. 2012 Jul; 14(7):919-30. doi: 10.1093/neuonc/nos112 PMID: 22561797
18. Semmineh NB, Xu J, Skinner JT, Xie J, Li H, Ayers G, et al. Assessing tumor cytoarchitecture using multiecho DSC-MRI derived measures of the transverse relaxivity at tracer equilibrium (TRATE). Magn Reson Med. 2014 Sep 16. doi: 10.1002/mrm.25435 PMID: 25227668
19. Jolliffe I. (2002). Principal component analysis. John Wiley & Sons, Ltd.
20. Eyal E, Bloch BN, Rofsky NM, Furman-Haran E, Genega EM, Lenkinski RE, et al. Principal component analysis of dynamic contrast enhanced MRI in human prostate cancer. Invest Radiol. 2010 Apr; 45 (4):174-81. doi: 10.1097/RLI.0b013e3181d0a02f PMID: 20177391
21. Yeung TP, Dekaban M, De Haan N, Morrison L, Hoffman L, Bureau Y, et al. Improving quantitative CT perfusion parameter measurements using principal component analysis. Acad Radiol. 2014 May; 21 (5):624-32. doi: 10.1016/j.acra.2014.01.015 PMID: 24703475
22. Lin GC, Wang WJ, Wang CM, Sun SY. Automated classification of multi-spectral MR images using Linear Discriminant Analysis. Comput Med Imaging Graph. 2010 Jun; 34(4):251-68. doi: 10.1016/j. compmedimag.2009.11.001 PMID: 20044236
23. Dixon SJ, Brereton RG. Comparison of performance of five common classifiers represented as boundary methods: Euclidean distance to centroids, linear discriminant analysis, quadratic discriminant analysis, learning vector quantization and support vector machines, as dependent on data structure. Chemometrics and Intelligent Laboratory Systems. 2009; 95(1), 1-17.
24. Zacharaki EI, Wang S, Chawla S, Yoo DS, Wolf R, Melhem ER, et al. Classification of brain tumor type and grade using MRI texture and shape in a machine learning scheme. Magn Reson Med. 2009 Dec; 62(6):1609-18. doi: 10.1002/mrm.22147 PMID: 19859947
25. Berens ME, Giese A. "⋯those left behind." Biology and oncology of invasive glioma cells. Neoplasia. 1999 Aug; 1(3):208-19. Review. PMID: 10935475
26. Sanai N, Polley MY, McDermott MW, Parsa AT, Berger MS. An extent of resection threshold for newly diagnosed glioblastomas. J Neurosurg. 2011 Jul; 115(1):3-8. doi: 10.3171/2011.2.JNS10998 PMID: 21417701
27. Roberts DW, Valdés PA, Harris BT, Fontaine KM, Hartov A, Fan X, et al. Coregistered fluorescenceenhanced tumor resection of malignant glioma: relationships between d-aminolevulinic acid-induced protoporphyrin IX fluorescence, magnetic resonance imaging enhancement, and neuropathological parameters. Clinical article. J Neurosurg. 2011 Mar; 114(3):595-603. doi: 10.3171/2010.2.JNS091322 PMID: 20380535
28. Valdés PA, Moses ZB, Kim A, Belden CJ, Wilson BC, Paulsen KD, et al. Gadolinium-and 5-aminolevulinic acid-induced protoporphyrin IX levels in human gliomas: an ex vivo quantitative study to correlate protoporphyrin IX levels and blood-brain barrier breakdown. J Neuropathol Exp Neurol. 2012 Sep; 71 (9):806-13. doi: 10.1097/NEN.0b013e31826775a1 PMID: 22878664
29. Pafundi DH, Laack NN, Youland RS, Parney IF, Lowe VJ, Giannini C, et al. Biopsy validation of 18FDOPA PET and biodistribution in gliomas for neurosurgical planning and radiotherapy target delineation: results of a prospective pilot study. Neuro Oncol. 2013 Aug; 15(8):1058-67. doi: 10.1093/neuonc/not002 PMID: 23460322
30. Hu LS, Baxter LC, Pinnaduwage DS, Paine TL, Karis JP, Feuerstein BG, et al. Optimized preload leakage-correction methods to improve the diagnostic accuracy of dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging in posttreatment gliomas. AJNR Am J Neuroradiol. 2010 Jan; 31 (1):40-8. doi: 10.3174/ajnr.A1787 Epub 2009 Sep 12. PMID: 19749223; PubMed Central PMCID: PMC4323177.